The clinical and humanistic burden of cutaneous T-cell lymphomas and response to conventional and novel therapies: results of a systematic review

Abstract

Objectives: To summarize the impact of relapsed/refractory primary cutaneous T-cell lymphomas (CTCL) on quality of life (QoL) and the efficacy of available treatments in two systematic reviews (SRs). Methods: Searches were performed on 16 January 2018 and 23 January 2018, respectively, in Medline, Medline in process, the Cochrane database, and EconLit. Studies reporting QoL outcomes in adults with CTCL or treatment efficacy in relapsed/refractory CTCL were included. Results: Based on 15 QoL studies, CTCL symptoms/complications negatively affect patients’ physical, emotional, and social functioning. Skin problems pose considerable symptom burden, while advanced disease stage is associated with poorer QoL. CTCL negatively affects caregivers, primarily through family dynamics and relationships. The clinical efficacy SR included 72 publications covering 23 therapies. Overall response rate (ORR) ranged from 14% (belinostat) to 95% (total skin electron beam therapy). ORRs >50% were reported for several therapies including brentuximab vedotin (50–78%) and bexarotene (39–86%). Over half (13 of 23 therapies) had ORRs <30%. Median progression-free survival varied between treatments (3.5–116.4 months) and was >20 months for brentuximab vedotin and alemtuzumab. Conclusion: CTCL negatively affects patients’ and caregivers’ QoL. A considerable proportion of patients have no response or no sustainable response to current treatments.